We can learn a tremendous amount about every cancer — including how to stop it — by sequencing a patient’s tumor, studying its unique metabolism, profiling the proteins it expresses, understanding the microenvironment it creates, tracking the immune system’s response, and characterizing the individual’s microbiome. This is precision oncology, and Fred Hutch scientists are at the forefront. Join us to hear from scientists who are using emerging technologies, ingenuity, and a growing volume and variety of molecular data to create personalized cancer therapies and prevention strategies.
Dr. Thomas J. Lynch Jr. is a distinguished health care leader, lung cancer doctor, and researcher. Since joining Fred Hutch as president and director in February 2020, he has led a robust scientific response to the pandemic while driving forward the cancer research at the heart of our mission. Prior to the Hutch, Tom led Yale Cancer Center and Massachusetts General Physicians Organization and served as chief scientific officer of Bristol-Myers Squibb. He holds the Raisbeck Endowed Chair.
Dr. Alice Berger explores how changes to our genetic code lead to cancer, and she translates these insights into new drug targets and markers for early disease detection. She is using the latest technology to uncover the cause of lung cancer in women who have never smoked, which is on the rise, and find new therapies for lung cancers that escape first-line treatment. Alice holds the Innovators Network Endowed Chair.
Dr. Christopher Li studies breast and colorectal cancer prevention, early detection, and survivorship. He co-leads Fred Hutch’s award-winning cancer registry and has used it to detect important connections between breast cancer and lifestyle factors such as obesity, alcohol use, and certain medications as well as to understand factors contributing to disparities in cancer outcomes. Chris is Vice President of Faculty Affairs and Diversity, and he holds the Helen G. Edson Endowed Chair for Breast Cancer Research.
Dr. Lucas Sullivan studies metabolism — what cells eat and how they process their food. He aims to understand how cancer cells exploit this process to outgrow nearby healthy cells and disarm immune cells that seek to destroy them. Lucas is developing a process that will enable immune cells to produce nutrients that are lacking in the microenvironment around a tumor, essentially re-arming them to successfully fight the cancer. This technology could give our engineered immunotherapies an advantage in fighting solid tumors.